Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2077

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 2077
---
 Company lacks effective
processes and controls to ensure the accuracy and completeness of its financial statements due to the lack of sufficient and qualified
resources. This material weakness led to the Company consistently failing to meet contractual deadlines for filing its financial statements.
In order to remediate the material weakness, the Company plans to hire additional qualified accounting personnel when the Company
has the financial resources to support such expenses, as well as engage consultants and purchase software licenses, if, and to the extent,
that the Company has sufficient financial resources for such additional expenses.

Management continues to evaluate
its plan to remediate the material weakness, which will not be considered remediated until management designs and implements effective
controls that operate for a sufficient period of time and management has concluded, through testing, that these controls are effective.

This Annual Report does not
include an attestation report of our independent registered public accounting firm due to our status as an emerging growth company under
the JOBS Act.

110

(c) Changes in Internal Control over Financial
Reporting

Other than described above, there
were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange
Act) during the year to which this Report relates that have materially affected or are reasonably likely to materially affect our internal
control over financial reporting. 

(d) Inherent Limitations on Effectiveness of Controls

Our disclosure controls and
procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving the desired control
objectives. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable
assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of
possible controls and procedures. Similarly, an evaluation of controls cannot provide absolute assurance that misstatements due to error
or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.

Item 9B. Other Information.

Rule 10b5-1 Plan or non-Rule
10b5-1 Trading Arrangements

During the three-month period
ended December 31, 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended)
adopted, terminated or modified a Rule 10b5-1 trading arrangement or any “non-Rule 10b